Donepezil attenuates Aβ-associated mitochondrial dysfunction and reduces mitochondrial Aβ accumulation in vivo and in vitro

Neuropharmacology

Volumn 95, Issue , 2015, Pages 29-36

  Ye, Chun Yan ^a   Lei, Yun ^a   Tang, Xi Can ^a   Zhang, Hai Yan ^a  

^a SHANGHAI INSTITUTE OF MATERIA MEDICA   (China)

Author keywords

Alzheimer's disease; Amyloid ; Donepezil; Mitochondrial dysfunction; Oligomer

Indexed keywords

ACETYLCHOLINESTERASE; ADENOSINE TRIPHOSPHATASE; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; CALCIUM ION; DONEPEZIL; AMYLOID PRECURSOR PROTEIN; APP PROTEIN, HUMAN; CHOLINESTERASE INHIBITOR; INDAN DERIVATIVE; NEUROPROTECTIVE AGENT; PIPERIDINE DERIVATIVE; PRESENILIN 1; PSEN1 PROTEIN, HUMAN;

ALZHEIMER DISEASE; AMNESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANXIETY; ARTICLE; BRAIN MITOCHONDRION; CELL MEMBRANE RESISTANCE; CELLULAR DISTRIBUTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DRUG EFFECT; ELEVATED PLUS MAZE TEST; ENZYME ACTIVITY; IN VITRO STUDY; IN VIVO STUDY; MALE; MENTAL DISEASE; MITOCHONDRIAL PERMEABILITY; MITOCHONDRION SWELLING; MOUSE; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; RAT; T-MAZE TEST; TRANSGENIC MOUSE; WILD TYPE; WORKING MEMORY; ANIMAL; BRAIN; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; GENETICS; HUMAN; METABOLISM; MITOCHONDRION; PATHOLOGY; RANDOMIZATION; SPRAGUE DAWLEY RAT;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BRAIN; CHOLINESTERASE INHIBITORS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; INDANS; MALE; MICE, TRANSGENIC; MITOCHONDRIA; NEUROPROTECTIVE AGENTS; PIPERIDINES; PRESENILIN-1; RANDOM ALLOCATION; RATS, SPRAGUE-DAWLEY;

EID: 84924995206     PISSN: 00283908     EISSN: 18737064     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2015.02.020     Document Type: Article

References (54)

1. Y. Abe, A. Aoyagi, T. Hara, K. Abe, R. Yamazaki, Y. Kumagae, S. Naruto, K. Koyama, S. Marumoto, K. Tago, N. Toda, K. Takami, N. Yamada, M. Ori, H. Kogen, and T. Kaneko Pharmacological characterization of RS-1259, an orally active dual inhibitor of acetylcholinesterase and serotonin transporter, in rodents: possible treatment of Alzheimer's disease J. Pharmacol. Sci. 93 2003 95 105
2. Alzheimer's Association 2014 Alzheimer's disease facts and figures Alzheimer's Dementia 10 2014 1 75
3. I. Benilova, E. Karran, and B. Strooper The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes Nat. Neurosci. 15 2012 349 357
4. X. Chen, and S.D. Yan Mitochondrial abeta: a potential cause of metabolic dysfunction in Alzheimer's disease IUBMB Life 58 2006 686 694
5. O. Cioanca, L. Hritcu, M. Mihasan, A. Trifan, and M. Hancianu Inhalation of coriander volatile oil increased anxiolytic-antidepressant-like behaviors and decreased oxidative status in β-amyloid (1-42) rat model of Alzheimer's disease Physiol. Behav. 131 2014 68 74
6. G. Colombo, R. Agabio, N. Balaklievskaia, C. Lobina, R. Reali, F. Fadda, and G.L. Gessa T-maze and food reinforcement: an inexpensive drug discrimination procedure J. Neurosci. Methods 67 1996 83 87
7. J.L. Cummings, M. Mega, K. Gray, S. Rosenberg-Thompson, D.A. Carusi, and J. Gornbein The neuropsychiatric inventory: comprehensive assessment of psychopathology in dementia Neurology 44 1994 2308 2314
8. R.M.J. Deacon, and J.N.P. Rawlins T-maze alternation in the rodent Nat. Protoc. 1 2006 7 12
9. N. Dragicevic, M. Mamcarz, Y. Zhu, R. Buzzeo, J. Tan, G.W. Arendash, and P.C. Bradshaw Mitochondrial amyloid-β levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice J. Alzheimers Dis. 20 Suppl. 2 2010 S535 S550
10. N. Dragicevic, A. Smith, X. Lin, F. Yuan, N. Copes, V. Delic, J. Tan, C. Cao, R.D. Shytle, and P.C. Bradshaw Green tea epigallocatechin-3-gallate (EGCG) and other flavonoids reduce Alzheimer's amyloid-induced mitochondrial dysfunction J. Alzheimers Dis. 26 2011 507 521
11. H. Du, L. Guo, F. Fang, D. Chen, A.A. Sosunov, G.M. McKhann, Y. Yan, C. Wang, H. Zhang, J.D. Molkentin, F.J. Gunn-Moore, J.P. Vonsattel, O. Arancio, J.X. Chen, and S.D. Yan Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease Nat. Med. 14 2008 1097 1105
12. H. Du, L. Guo, S. Yan, A.A. Sosunov, G.M. McKhann, and S.S. Yan Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model Proc. Natl. Acad. Sci. U. S. A. 107 2010 18670 18675
13. S. Gandy, and S.T. DeKosky Toward the treatment and prevention of Alzheimer's disease: rational strategies and recent progress Annu Rev. Med. 64 2013 367 383
14. X. Gao, and X.C. Tang Huperzine A attenuates mitochondrial dysfunction in β-amyloid-treated PC12 cells by reducing oxygen free radicals accumulation and improving mitochondrial energy metabolism J. Neurosci. Res. 83 2006 1048 1057
15. E. Giacobini, and G. Gold Alzheimer disease therapy-moving from amyloid-β to tau Nat. Rev. Neurol. 9 2013 677 686
16. C.W. Goh, C.C. Aw, J.H. Lee, C.P. Chen, and E.R. Browne Pharmacokinetic and pharmacodynamic properties of cholinesterase inhibitors donepezil, tacrine, and galantamine in aged and young lister hooded rats Drug Metab. Dispos. 39 2011 402 411
17. W.F. Goure, G.A. Krafft, J. Jerecic, and F. Hefti Targeting the proper amyloid-beta neuronal toxins: a path forward for Alzheimer's disease immunotherapeutics Alzheimers Res. Ther. 6 2014 42
18. M. Hadamitzky, A. Herring, K. Keyvani, R. Doenlen, U. Krugel, K. Bosche, K. Orlowski, H. Engler, and M. Schedlowski Acute systemic rapamycin induces neurobehavioral alterations in rats Behav. Brain Res. 273 2014 16 22
19. C.A. Hansson Petersen, N. Alikhani, H. Behbahani, B. Wiehager, P.F. Pavlov, I. Alafuzoff, V. Leinonen, A. Ito, B. Winblad, E. Glaser, and M. Ankarcrona The amyloid β-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae Proc. Natl. Acad. Sci. U. S. A. 105 2008 13145 13150
20. M. Hashimoto, H. Kazui, K. Matsumoto, Y. Nakano, M. Yasuda, and E. Mori Does donepezil treatment slow the progression of hippocampal atrophy in patients with Alzheimer's disease? Am. J. Psychiatry 162 2005 676 682
21. J. He, H. Luo, B. Yan, Y. Yu, H. Wang, Z. Wei, Y. Zhang, H. Xu, A. Tempier, X. Li, and X.M. Li Beneficial effects of quetiapine in a transgenic mouse model of Alzheimer's disease Neurobiol. Aging 30 2009 1205 1216
22. 1-42 on neural progenitor cell proliferation Neurobiol. Aging 35 2014 975 989
23. H.S. Kim, J.H. Lee, J.P. Lee, E.M. Kim, K.A. Chang, C.H. Park, S.J. Jeong, M.C. Wittendorp, J.H. Seo, S.H. Choi, and Y.H. Suh Amyloid β peptide induces cytochrome C release from isolated mitochondria Neuroreport 13 2002 1989 1993
24. F.M. LaFerla, K.N. Green, and S. Oddo Intracellular amyloid-β in Alzheimer's disease Nat. Rev. Neurosci. 8 2007 499 509
25. M.P. Lambert, A.K. Barlow, B.A. Chromy, C. Edwards, R. Freed, M. Liosatos, T.E. Morgans, I. Rozovsky, B. Trommer, K.L. Viola, P. Wals, C. Zhang, C.E. Finch, G.A. Krafft, and W.L. Klein Diffusible, nonfibrillar ligands derived from Aβ are potent central nervous system neurotoxins Proc. Natl. Acad. Sci. U. S. A. 95 1998 6448 6453
26. C. Le Cudennec, A. Faure, M. Ly, and B. Delatour One-year longitudinal evaluation of sensorimotor functions in APP751SL transgenic mice Genes. Brain Behav. 7 Suppl. 1 2008 83 91
27. K. Lok, H. Zhao, C. Zhang, N. He, H. Shen, Z. Wang, W. Zhao, and M. Yin Effects of accelerated senescence on learning and memory, locomotion and anxiety-like behavior in APP/PS1 mouse model of Alzheimer's disease J. Neurol. Sci. 335 2013 145 154
28. M. Manczak, T.S. Anekonda, E. Henson, B.S. Park, J. Quinn, and P.H. Reddy Mitochondria are a direct site of Aβ accumulation in Alzheimer's disease neurons: implications for free radical generation and oxidative damage in disease progression Hum. Mol. Genet. 15 2006 1437 1449
29. F. Mangialasche, A. Solomon, B. Winblad, P. Mecocci, and M. Kivipelto Alzheimer's disease: clinical trials and drug development Lancet Neurol. 9 2010 702 716
30. P.L. McClean, and C. Holscher Lixisenatide, a drug developed to treat type 2 diabetes, shows neuroprotective effects in a mouse model of Alzheimer's disease Neuropharmacology 86 2014 241 258
31. M.S. Mega, J.L. Cummings, T. Fiorello, and J. Gornbein The spectrum of behavioral changes in Alzheimer's disease Neurology 46 1996 130 135
32. 25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor Br. J. Pharmacol. 149 2006 998 1012
33. P. Narayan, K.M. Holmstrom, D.H. Kim, D.J. Whitcomb, M.R. Wilson, P. St George-Hyslop, N.W. Wood, C.M. Dobson, K. Cho, A.Y. Abramov, and D. Klenerman Rare individual amyloid-β oligomers act on astrocytes to initiate neuronal damage Biochemistry 53 2014 2442 2453
34. R. Nirogi, G. Bhyrapuneni, V. Kandikere, V. Benade, N. Muddana, R. Saralaya, S. Irappanavar, R. Ponnamaneni, and K. Mukkanti Concurrent administration of atypical antipsychotics and donepezil: drug interaction study in rats Eur. J. Drug Metab. Pharmacokinet. 37 2012 155 161
35. Y. Noda, A. Mouri, Y. Ando, Y. Waki, S. Yamada, A. Yoshimi, K. Yamada, N. Ozaki, D. Wang, and T. Nabeshima Galantamine ameliorates the impairment of recognition memory in mice repeatedly treated with methamphetamine: involvement of allosteric potentiation of nicotinic acetylcholine receptors and dopaminergic-ERK1/2 systems Int. J. Neuropsychopharmacol. 13 2010 1343 1354
36. M.-Y. Noh, S.-H. Koh, Y. Kim, H.Y. Kim, G.W. Cho, and S.H. Kim Neuroprotective effects of donepezil through inhibition of GSK-3 activity in amyloid-β-induced neuronal cell death J. Neurochem. 108 2009 1116 1125
37. R.C. Petersen, G.E. Smith, S.C. Waring, R.J. Ivnik, E.G. Tangalos, and E. Kokmen Mild cognitive impairment: clinical characterization and outcome Arch. Neurol. 56 1999 303 308
38. B.L. Plassman, K.M. Langa, G.G. Fisher, S.G. Heeringa, D.R. Weir, M.B. Ofstedal, J.R. Burke, M.D. Hurd, G.G. Potter, W.L. Rodgers, D.C. Steffens, R.J. Willis, and R.B. Wallace Prevalence of dementia in the United States: the aging, demographics, and memory study Neuroepidemiology 29 2007 125 132
39. S.L. Risacher, and A.J. Saykin Neuroimaging and other biomarkers for Alzheimer's disease: the changing landscape of early detection Annu Rev. Clin. Psychol. 9 2013 621 648
40. C.M. Rodrigues, S. Sola, R. Silva, and D. Brites Bilirubin and amyloid-β peptide induce cytochrome c release through mitochondrial membrane permeabilization Mol. Med. 6 2000 936 946
41. C. Romberg, M.P. Mattson, M.R. Mughal, T.J. Bussey, and L.M. Saksida Impaired attention in the 3xTgAD mouse model of Alzheimer's disease: rescue by donepezil (Aricept) J. Neurosci. 31 2011 3500 3507
42. P. Sarkar, I. Zaja, M. Bienengraeber, K.R. Rarick, M. Terashvili, S. Canfield, J.R. Falck, and D.R. Harder Epoxyeicosatrienoic acids pretreatment improves amyloid β-induced mitochondrial dysfunction in cultured rat hippocampal astrocytes Am. J. Physiol. Heart Circ. Physiol. 306 2014 H475 H484
43. D.J. Selkoe Altered structural proteins in plaques and tangles: what do they tell us about the biology of Alzheimer's disease? Neurobiol. Aging 7 1986 425 432
44. G.M. Shankar, S. Li, T.H. Mehta, A. Garcia-Munoz, N.E. Shepardson, I. Smith, F.M. Brett, M.A. Farrell, M.J. Rowan, C.A. Lemere, C.M. Regan, D.M. Walsh, B.L. Sabatini, and D.J. Selkoe Amyloid-β protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory Nat. Med. 14 2008 837 842
45. J.C. Soares, M.G. Oliveira, and T.L. Ferreira Inactivation of muscarinic receptors impairs place and response learning: implications for multiple memory systems Neuropharmacology 73 2013 320 326
46. 1-42 neurotoxicity by inhibiting the mitochondrial permeability transition pore opening PLoS One 9 2014 e98866
47. K. Takuma, J. Yao, J. Huang, H. Xu, X. Chen, J. Luddy, A.C. Trillat, D.M. Stern, O. Arancio, and S.S. Yan ABAD enhances Abeta-induced cell stress via mitochondrial dysfunction FASEB J. 19 2005 597 598
48. 1-42-induced neurotoxicity in vitro and in vivo Neurobiol. Aging 35 2014 590 599
49. A.A. Walf, and C.A. Frye The use of the elevated plus maze as an assay of anxiety-related behavior in rodents Nat. Protoc. 2 2007 322 328
50. K.C. Walls, P. Coskun, J.L. Gallegos-Perez, N. Zadourian, K. Freude, S. Rasool, M. Blurton-Jones, K.N. Green, and F.M. LaFerla Swedish Alzheimer mutation induces mitochondrial dysfunction mediated by HSP60 mislocalization of amyloid precursor protein (APP) and β-amyloid J. Bio. Chem. 287 2012 30317 30327
51. J. Wang, H.Y. Zhang, and X.C. Tang Huperzine A improves chronic inflammation and cognitive decline in rats with cerebral hypoperfusion J. Neurosci. Res. 88 2010 807 815
52. G. Winocur, M.A. Binns, and I. Tannock Donepezil reduces cognitive impairment associated with anti-cancer drugs in a mouse model Neuropharmacology 61 2011 1222 1228
53. L. Yang, C.Y. Ye, X.T. Huang, X.C. Tang, and H.Y. Zhang Decreased accumulation of subcellular amyloid-beta with Improved mitochondrial function mediates the neuroprotective effect of Huperzine A J. Alzheimers Dis. 31 2012 131 142
54. J. Yao, H. Du, S. Yan, F. Fang, C. Wang, L.F. Lue, L. Guo, D. Chen, D.M. Stern, F.J. Gunn Moore, J. Xi Chen, O. Arancio, and S.S. Yan Inhibition of amyloid-β (Aβ) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Aβ accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease J. Neurosci. 31 2011 2313 2320